MAPT and Alzheimer disease: Current non-invasive diagnostic markers for AD include the deposition of amyloid-β (Aβ) peptides into plaques detected by positron emission tomography (PET) scans, along with Aβ and phosphorylated tau peptide (p-Tau) detection in serum and cerebrospinal fluid (CSF) [4,5].